NUCYNTA ER Drug Patent Profile

When do Nucynta Er patents expire, and when can generic versions of Nucynta Er launch?

Nucynta Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in twenty-two countries.

The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tapentadol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nucynta Er

A generic version of NUCYNTA ER was approved as tapentadol hydrochloride by NOVITIUM PHARMA on January 26^th, 2026.

Summary for NUCYNTA ER

International Patents:	51
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NUCYNTA ER

Paragraph IV (Patent) Challenges for NUCYNTA ER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUCYNTA ER	Extended-release Tablets	tapentadol hydrochloride	50 mg, 100 mg, 150 mg, 200 mg, and 250 mg	200533	2	2012-11-20

US Patents and Regulatory Information for NUCYNTA ER

NUCYNTA ER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-001	Aug 25, 2011		RX	Yes	No	8,536,130*PED				Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-004	Aug 25, 2011		RX	Yes	No	8,536,130*PED				Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No	11,344,512*PED				Y
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-004	Aug 25, 2011		RX	Yes	No	11,344,512*PED				Y

International Patents for NUCYNTA ER

See the table below for patents covering NUCYNTA ER around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	341239
Japan	2012102130	COMPOUND ACTIVE AT NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNEL USEFUL FOR TREATMENT OF NERVE DISORDER AND NERVOUS DISEASE
Denmark	1612203
Japan	6745959

Supplementary Protection Certificates for NUCYNTA ER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0693475	C300541	Netherlands		PRODUCT NAME: TAPENTADOL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TAPENTADOL HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 110721-110724 RVG 110728-110731 20120316; FIRST REGISTRATION: DE 75043.00.00 - 75045.00.00, 75046.00.00, 76261.00.00 - 76270.00.00 20120819
0693475	PA2011007,C0693475	Lithuania		PRODUCT NAME: TAPENTADOLUM; NAT. REGISTRATION NO/DATE: LT/1/10/2341/001 - LT/1/10/2341/66, 2011 02 19; LT/1/10/2342/001 - LT/1/10/2342/110 20110219; FIRST REGISTRATION: 75043.00.00 - 75048.00.00, 2010 08 19; 76261.00.00 - 76270.00.00 20100819
1439829	C 2011 002	Romania		PRODUCT NAME: TAPENTADOL SAU O SARE ACCEPTABILA FARMACEUTIC AACESTUIA; NATIONAL AUTHORISATION NUMBER: RO 3279/2011/01 - RO 3279/2011/22; DATE OF NATIONAL AUTHORISATION: 20110228; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): DE 75.046; DATE OF FIRST AUTHORISATION IN EEA: 20100819
0693475	CR 2010 00036	Denmark		PRODUCT NAME: TAPENTADOL ((1R-2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL), HERUNDER HYDROCHLORIDET; NAT. REG. NO/DATE: 45151-45158, 45162-45169 20100830; FIRST REG. NO/DATE: EU 75043.00.00-75048.00.00, 75261.00.00-75270.00.00 20100819

Summary

Last updated: February 3, 2026

This analysis explores the investment landscape, market dynamics, and financial trajectory of NUCYNTA ER (Tapentadol Extended-Release), a prescription opioid analgesic. Developed primarily for chronic pain management, NUCYNTA ER holds a significant position amidst growing opioid use, regulatory considerations, and competitive pressures. The report evaluates current market size, growth drivers, risks, and future financial forecasts to aid stakeholders' decision-making.

What Is the Current Market Position of NUCYNTA ER?

NUCYNTA ER is manufactured by Janssen Pharmaceuticals, a division of Johnson & Johnson. It received FDA approval in 2013 for moderate to severe chronic pain. The drug’s sales and market penetration are influenced by factors such as:

• Market Size: The global chronic pain management market was valued at approximately $73 billion in 2021, projected to grow at a CAGR of around 4% through 2028 [1].

• Market Position: NUCYNTA ER is among several extended-release opioids, competing against products like OxyContin (opioid), Morphine ER, and other non-opioid pain therapies.

• Regulatory Environment: Stringent regulations and shifting prescribing guidelines impact sales volume.

How Do Market Dynamics Influence NUCYNTA ER?

1. Regulatory and Legal Risks

• Increased scrutiny over opioid medications hampers growth prospects.
• US DOJ and FDA enforcement actions have led to reformulations, label warnings, and prescribing restrictions.
• Litigation risks associated with opioid liability cases present potential negative financial exposure.

2. Pharmacovigilance and Prescribing Patterns

• Growing emphasis on abuse-deterrent formulations (ADFs) affects product strategy.
• Shift towards non-opioid alternatives (gabapentinoids, NSAIDs) as first-line treatments.

3. Competitive Landscape

Competitors	Product Name	Market Share (Approximate)	Key Factors
Purdue Pharma	OxyContin	25-30%	Established brand, abuse-deterrent formulations
MundiPharma	Morphine ER	10-15%	Cost advantage, global reach
Private-label Opioids	Various	10-12%	Lower cost, regional distribution
Non-opioid alternatives	NSAIDs, Gabapentinoids, etc.	20-30%	Safety profile, regulatory push

4. Market Trends

• Transition Towards Multi-modal Pain Management: Combining opioids with adjuvants to reduce doses.
• Rise of Non-Opioid Analgesics: NSAIDs, antiepileptics, and antidepressants are gaining importance.
• Regulatory Incentives for Safer Formulations: Development of abuse-deterrent, tamper-resistant tablets.

What Are the Financial Trajectories for NUCYNTA ER?

Historical Revenue Data (Approximate, USD millions):

Year	Revenue	Year-over-Year Change	Notes
2017	370	-	Peak pre-regulation adjustments
2018	340	-8%	Market saturation, regulatory pressures
2019	310	-9%	Continued decline
2020	290	-6%	COVID-19 pandemic impact
2021	250	-13%	Competition intensifies

Forecast (Next 5 Years):

Year	Estimated Revenue Range (USD millions)	Assumptions
2023	200-250	Regulatory constraints, rising non-opioid use, reformulation efforts
2025	180-220	Continued market share erosion, regulatory pressures
2028	150-200	Mature market stabilization, potential new formulations

Note: The decline reflects market pressures and limited pipeline expansion.

Investment implications:

• Potential for niche or specialty adoption if focused on pediatric or controlled-release markets.
• Reformulation or line extensions may temporarily boost revenue.
• Generic competition persists, but patent exclusivity undecided post-2023.

How Does Legal and Policy Environment Impact Financial Outlook?

• Opioid Crisis Response: US CDC guidelines recommend cautious prescribing, suppressing aggressive sales.
• Legal Proceedings: Multi-billion-dollar legal settlements threaten revenue streams.
• Reimbursement Policies: Payers increasingly restrict coverage for high-risk opioids.
• FDA Enforcement: Focal point on abuse-deterrent formulations, which entails R&D investments.

What Are the Investment Risks and Opportunities?

Risks:

Risk Category	Details
Regulatory restrictions	Prescribing limits, formulary restrictions, market access
Litigation exposure	Liability claims, class actions, settlement costs
Market attrition	Competition, patent cliffs, shifting prescribing trends
Public perception	Negative media reports, altered patient behaviors

Opportunities:

Opportunity Category	Details
Reformulation projects	Abuse-deterrent formulations, new delivery systems
Market expansion	Emerging markets with less regulation
Line extensions	Combination products, novel indications
Strategic partnerships	Collaborations with specialty clinics or pain management centers

Comparing NUCYNTA ER to Alternative Pain Management Solutions

Aspect	NUCYNTA ER	Non-Opioid Alternatives	Other Extended-Release Opioids
Market Position	Moderate competitor	Growing market segment	Dominant players with established sales
Regulatory Risk	High	Lower	Similar or higher
Abuse-Deterrent Technology	Yes (reformulations)	Variable	Varies
Pricing	Premium	Lower	Comparable
Market Growth Potential	Limited post-2023	Accelerated, especially for non-opioids	Steady, mature market

What Are the Regulatory Policies and Patent Lifespan?

Policy/Regulation	Impact	Key Dates
FDA Abuse-Deterrent Guidelines	Drives reformulation strategies	Published 2015, updated 2019
US CDC Opioid Prescribing Guidelines	Promotes cautious use, restricting prescriptions	2016
Patent Expiry	Approximately 2023 (for primary formulation)	Patents filed 2010-2015, expiring 2023
State-level Restrictions	Variable, impacts market adoption	2018-present

Key Takeaways

• Market Size & Growth: NUCYNTA ER's market has been declining due to regulatory and competitive pressures. Growth prospects are limited, with revenues forecasted to decrease further unless significant repositioning occurs.

• Regulatory Risk & Legal Exposure: Intensified scrutiny, including legal liabilities, threaten financial stability. Reformulation efforts targeting abuse deterrence could partially offset declines but require significant investment.

• Competition & Market Trends: Increasing preference for non-opioid pain treatments and abuse-deterrent formulations place pressure on traditional opioids like NUCYNTA ER.

• Investment Strategy: Short-to-medium-term investments should consider potential declines balanced against opportunities in niche markets, reformulations, or pipeline development. Long-term prospects hinge on regulatory changes, pipeline innovation, and market shifts toward multimodal pain management.

Frequently Asked Questions

1. What is the projected market share of NUCYNTA ER over the next five years?
Given current trends, NUCYNTA ER's market share is expected to decline from approximately 3-4% of the chronic pain opioid market to below 2%, contingent upon reformulation success and market acceptance.

2. Are there opportunities for NUCYNTA ER in emerging markets?
Yes. Some emerging markets have less restrictive opioid regulations and growing pain management needs, potentially providing growth avenues, though regulatory landscapes vary.

3. How does reformulation impact NUCYNTA ER’s patent protections?
Reformulations, primarily abuse-deterrent versions, can extend patent life or provide new IP, delaying generic competition. However, patent cliffs are imminent for some formulations, increasing exposure to generics.

4. What is the significance of abuse-deterrent formulations for NUCYNTA ER?
Abuse-deterrent formulations can mitigate regulatory risks and potentially expand prescriber acceptance; they are central to future R&D strategies but entail high costs and uncertain regulatory approval pathways.

5. How do payer policies influence NUCYNTA ER’s market viability?
Payer restrictions, formulary exclusions, and prior authorization requirements limit prescribing, reducing sales volume and revenue potential.

References

1. Grand View Research, Inc., "Chronic Pain Management Market Size, Share & Trends Analysis Report," 2022.

2. FDA, "Guidance for Industry: Abuse-Deterrent Packaging and Labeling of Opioid Medications," 2015.

3. CDC, "CDC Guideline for Prescribing Opioids for Chronic Pain," 2016.

4. Johnson & Johnson, investor reports, 2017-2021.

5. MarketWatch, "Global Opioids Market Outlook," 2022.

---

Note: All data and projections are for informational purposes and subject to market volatility and regulatory developments.